Impact of New Biomarkers on Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation (Biorhythm)
Impact of New Biomarkers on the Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Besancon, France, 25000
- University Hospital Jean Minjoz
-
Dijon, France
- CHU François Mitterand
-
Vandoeuvre les nancy, France
- CHU Brabois
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with paroxystic or persistent atrial fibrillation for whom a decision to perform ablation is made.
- Patients with persistent atrial fibrillation for whom a decision to perform cardioversion is made.
- Patients with social security coverage, or beneficiary thereof.
- Patients who provide written informed consent.
Exclusion Criteria:
- Age <18 years or >80 years
- Patients with significant valvular heart disease defined as symptomatic aortic valve disease, severe aortic or mitral stenosis or tricuspid or mitral insufficiency grade 3/4 or 4/4
- Patients with pulmonary arterial hypertension >45 mmHg on echocardiography
- Patients with chronic respiratory disease, chronic obstructive pulmonary disease stage II, III or IV.
- Patients with a left ventricular ejection fraction <45%
- Patients with recent (<1 month) acute decompensation of heart failure
- Patients with recent (<1 month) acute coronary syndrome
- Anemia (hemoglobin <10 g/dL)
- Pregnant or lactating women
- Patients with anticipated poor compliance, as assessed by the study investigator
- Patients within the exclusion period of another clinical study
- Patients under legal guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cardioversion group
Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
|
External electric shock delivery under general anesthesia.
|
|
Experimental: Ablation group
Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
|
Pulmonary vein isolation by radiofrequency or cryoablation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrent atrial fibrillation
Time Frame: 12 months
|
Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.
|
12 months
|
|
Recurrent atrial tachycardia
Time Frame: 12 months
|
Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.
|
12 months
|
|
Recurrent flutter
Time Frame: 12 months
|
Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrent atrial fibrillation
Time Frame: 3 months
|
Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.
|
3 months
|
|
Recurrent atrial tachycardia
Time Frame: 3 months
|
Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.
|
3 months
|
|
Recurrent flutter
Time Frame: 3 months
|
Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.
|
3 months
|
|
Palpitations
Time Frame: 12 months
|
Any episode of palpitation occurring during follow-up
|
12 months
|
|
Hospitalization
Time Frame: 12 months
|
Hospital admission related to atrial fibrillation, atrial tachycardia or flutter during follow-up
|
12 months
|
|
Repeat ablation
Time Frame: 12 months
|
Need for repeat ablation during follow-up in patients who underwent ablation of AF
|
12 months
|
|
Cardioversion
Time Frame: 12 months
|
Need for electric or medical cardioversion during follow-up (all patients, regardless of initial intervention type)
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Nicolas Meneveau, MD, PhD, Centre Hospitalier Universitaire de Besancon
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017-A00731-52
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.